Deal round-up 22/04/02

Atlas leads E20m Axovan financing; Apovia raises E19m

Atlas leads E20m Axovan financing

Axovan, the Swiss-based drug development company, has announced a E20.5m financing round led by UK private equity firm Atlas Ventures. New investors in the firm comprised Heidelberg Innovation, NeoMed, Banque Cantonale Vaudoise Private Equity in addition to all of the firm’s first round backers.

the first round of E5.5m was raised in June 2000 from Swiss investors New Medical Technologies, Venture Partners and Genevest. The proceeds of this recent financing will be used primarily to accelerate the firm’s research and development technology.

Apovia raises E19m

Apovia AG, a private German biotech company developing vaccines for the prevention and treatment of infectious diseases, has completed a third-round fundraising worth E19m. The financing was led by Heidelberg Innovation. Other investors include Genavent, Societe Generale Asset Management and VCH Equity Group AG.

Previous investors, including 3i, Global Life Science Holding II GmbH and Oxford Bioscience Partners, also backed the latest fundraising round. Arthur Andersen Corporate Finance acted as advisers to Apovia. The firm will use the new funds to develop its pipeline of products in clinical and pre-clinical trials.